ID

14565

Beskrivning

Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01031368

Länk

https://clinicaltrials.gov/show/NCT01031368

Nyckelord

Versioner (1)
  1. 2016-04-21 2016-04-21 -
Uppladdad den

21 april 2016

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Adult Acute Megakaryoblastic Leukemia (M7) NCT01031368

Engelsk

Eligibility Adult Acute Megakaryoblastic Leukemia (M7) NCT01031368

1 Formulär  
Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
cohort a: diagnosis of aml by world health organization (who) criteria, either relapsed or refractory; acute promyelocytic leukemia [acute promyelocytic leukemia with t(15;17)(q22;q12) and variants] will be eligible only after failure of a regimen containing arsenic trioxide; patients in this cohort must have had an initial remission duration of < 1 year and cannot have received any prior salvage chemotherapy
Beskrivning

aml

Datatyp

boolean

Alias
UMLS CUI [1]
C0023467
cohort b: untreated aml patients, excluding those with favorable cytogenetic or molecular abnormalities per the european leukemianet recommendations
Beskrivning

untreated aml

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0023467
UMLS CUI [1,2]
C0332155
cohort c: untreated aml patients, including those with favorable cytogenetic or molecular abnormalities per the european leukemianet recommendations
Beskrivning

untreated aml

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0023467
UMLS CUI [1,2]
C0332155
UMLS CUI [1,3]
C0010802
the first three patients enrolled in cohorts a and b must be less than 60 years old; thereafter, patients aged >= 18 and =< 70 are eligible
Beskrivning

age

Datatyp

boolean

Alias
UMLS CUI [1]
C0001779
the first three patients enrolled in cohorts a and b must have an eastern cooperative oncology group (ecog) performance status of 0 -1; thereafter, ecog performance status of 0-2 is required
Beskrivning

eastern cooperative oncology group (ecog) performance status

Datatyp

boolean

Alias
UMLS CUI [1]
C1520224
serum creatinine =< 1.0 mg/dl; if serum creatinine > 1.0 mg/dl, then the estimated glomerular filtration rate (gfr) must be > 60 ml/min/1.73 m^2 as calculated by the modification of diet in renal disease equation where predicted gfr (ml/min/1.73 m^2) = 186 x (serum creatinine)^-1.154 x (age in years)^-0.203 x (0.742 if patient is female) x (1.212 if patient is black)
Beskrivning

serum creatinine

Datatyp

boolean

Alias
UMLS CUI [1]
C0201976
serum total bilirubin =< 1.5 x upper limit of normal (uln) unless elevation is thought to be due to gilbert's syndrome, hemolysis, or hepatic infiltration by the hematologic malignancy
Beskrivning

serum total bilirubin

Datatyp

boolean

Alias
UMLS CUI [1]
C1278039
aspartate aminotransferase (ast)/alanine aminotransferase (alt) =< 2.5 x uln, unless elevation is thought to be due to hepatic infiltration by the hematologic malignancy
Beskrivning

aspartate aminotransferase

Datatyp

boolean

Alias
UMLS CUI [1]
C0201899
alkaline phosphatase =< 2.5 x uln
Beskrivning

alkaline phosphatase

Datatyp

boolean

Alias
UMLS CUI [1]
C1561546
capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent
Beskrivning

informed consent

Datatyp

boolean

Alias
UMLS CUI [1]
C0021430
female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment
Beskrivning

negative serum pregnancy test

Datatyp

boolean

Alias
UMLS CUI [1]
C0430061
male and female patients must be willing to use an effective contraceptive method during the study and for a minimum of 90 days after study treatment
Beskrivning

Contraceptive methods

Datatyp

boolean

Alias
UMLS CUI [1]
C0700589
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
allogeneic transplant recipients
Beskrivning

allogeneic transplant

Datatyp

boolean

Alias
UMLS CUI [1]
C0149615
cytotoxic chemotherapy, radiation therapy, immunosuppressants, or cytokine treatment within 4 weeks prior to study entry or persistent clinical evidence of toxicity.
Beskrivning

chemotherapy, radiation therapy, immunosuppressants, or cytokine treatment

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C1522449
UMLS CUI [1,3]
C0021081
UMLS CUI [1,4]
C0199974
have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver (including symptomatic hepatitis, veno-occlusive disease), or other organ system dysfunction
Beskrivning

concurrent disease

Datatyp

boolean

Alias
UMLS CUI [1]
C0009488
patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
Beskrivning

systemic infection and inflammation

Datatyp

boolean

Alias
UMLS CUI [1]
C3646020
pregnant or lactating patients
Beskrivning

pregnant or lactating

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0549206
UMLS CUI [1,2]
C0006147
any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results
Beskrivning

compliance

Datatyp

boolean

Alias
UMLS CUI [1]
C0525058
UMLS CUI [2]
C0009488
Tillbaka till toppen

Similar models

Eligibility Adult Acute Megakaryoblastic Leukemia (M7) NCT01031368

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
aml
Item
cohort a: diagnosis of aml by world health organization (who) criteria, either relapsed or refractory; acute promyelocytic leukemia [acute promyelocytic leukemia with t(15;17)(q22;q12) and variants] will be eligible only after failure of a regimen containing arsenic trioxide; patients in this cohort must have had an initial remission duration of < 1 year and cannot have received any prior salvage chemotherapy
boolean
C0023467 (UMLS CUI [1])
untreated aml
Item
cohort b: untreated aml patients, excluding those with favorable cytogenetic or molecular abnormalities per the european leukemianet recommendations
boolean
C0023467 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
untreated aml
Item
cohort c: untreated aml patients, including those with favorable cytogenetic or molecular abnormalities per the european leukemianet recommendations
boolean
C0023467 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C0010802 (UMLS CUI [1,3])
age
Item
the first three patients enrolled in cohorts a and b must be less than 60 years old; thereafter, patients aged >= 18 and =< 70 are eligible
boolean
C0001779 (UMLS CUI [1])
eastern cooperative oncology group (ecog) performance status
Item
the first three patients enrolled in cohorts a and b must have an eastern cooperative oncology group (ecog) performance status of 0 -1; thereafter, ecog performance status of 0-2 is required
boolean
C1520224 (UMLS CUI [1])
serum creatinine
Item
serum creatinine =< 1.0 mg/dl; if serum creatinine > 1.0 mg/dl, then the estimated glomerular filtration rate (gfr) must be > 60 ml/min/1.73 m^2 as calculated by the modification of diet in renal disease equation where predicted gfr (ml/min/1.73 m^2) = 186 x (serum creatinine)^-1.154 x (age in years)^-0.203 x (0.742 if patient is female) x (1.212 if patient is black)
boolean
C0201976 (UMLS CUI [1])
serum total bilirubin
Item
serum total bilirubin =< 1.5 x upper limit of normal (uln) unless elevation is thought to be due to gilbert's syndrome, hemolysis, or hepatic infiltration by the hematologic malignancy
boolean
C1278039 (UMLS CUI [1])
aspartate aminotransferase
Item
aspartate aminotransferase (ast)/alanine aminotransferase (alt) =< 2.5 x uln, unless elevation is thought to be due to hepatic infiltration by the hematologic malignancy
boolean
C0201899 (UMLS CUI [1])
alkaline phosphatase
Item
alkaline phosphatase =< 2.5 x uln
boolean
C1561546 (UMLS CUI [1])
informed consent
Item
capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent
boolean
C0021430 (UMLS CUI [1])
negative serum pregnancy test
Item
female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment
boolean
C0430061 (UMLS CUI [1])
Contraceptive methods
Item
male and female patients must be willing to use an effective contraceptive method during the study and for a minimum of 90 days after study treatment
boolean
C0700589 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
allogeneic transplant
Item
allogeneic transplant recipients
boolean
C0149615 (UMLS CUI [1])
chemotherapy, radiation therapy, immunosuppressants, or cytokine treatment
Item
cytotoxic chemotherapy, radiation therapy, immunosuppressants, or cytokine treatment within 4 weeks prior to study entry or persistent clinical evidence of toxicity.
boolean
C0392920 (UMLS CUI [1,1])
C1522449 (UMLS CUI [1,2])
C0021081 (UMLS CUI [1,3])
C0199974 (UMLS CUI [1,4])
concurrent disease
Item
have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver (including symptomatic hepatitis, veno-occlusive disease), or other organ system dysfunction
boolean
C0009488 (UMLS CUI [1])
systemic infection and inflammation
Item
patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
boolean
C3646020 (UMLS CUI [1])
pregnant or lactating
Item
pregnant or lactating patients
boolean
C0549206 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
compliance
Item
any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results
boolean
C0525058 (UMLS CUI [1])
C0009488 (UMLS CUI [2])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial